Ligand Pharmaceuticals (LGND) Gains from Investment Securities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Gains from Investment Securities across 17 years of filings, most recently posting $7000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $7000.0, down 99.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.6 million (down 3032.59% YoY), and the FY2025 annual result was $2.3 million, down 7.4% from the prior year.
• Gains from Investment Securities came in at $7000.0 for Q1 2026 at Ligand Pharmaceuticals, up from -$6.7 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $4.2 million in Q1 2023 to a low of -$6.7 million in Q3 2025.
• The 5-year median for Gains from Investment Securities is $45000.0 (2023), against an average of -$214933.3.
• Across the five-year window, Gains from Investment Securities jumped 31861.54% in 2023 and slumped 1657.78% in 2024, its largest moves.
• Ligand Pharmaceuticals' Gains from Investment Securities stood at $80000.0 in 2022, then sank by 43.75% to $45000.0 in 2023, then plunged by 1657.78% to -$701000.0 in 2024, then sank by 858.77% to -$6.7 million in 2025, then soared by 100.1% to $7000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $7000.0 (Q1 2026), -$6.7 million (Q3 2025), and $145000.0 (Q2 2025), per Business Quant data.